IL110190A - Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity - Google Patents

Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity

Info

Publication number
IL110190A
IL110190A IL11019094A IL11019094A IL110190A IL 110190 A IL110190 A IL 110190A IL 11019094 A IL11019094 A IL 11019094A IL 11019094 A IL11019094 A IL 11019094A IL 110190 A IL110190 A IL 110190A
Authority
IL
Israel
Prior art keywords
manufacture
medicaments
preparation
acid secretion
protective activity
Prior art date
Application number
IL11019094A
Other languages
English (en)
Other versions
IL110190A0 (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL110190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL110190A0 publication Critical patent/IL110190A0/xx
Publication of IL110190A publication Critical patent/IL110190A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Contacts (AREA)
  • Conductive Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Powder Metallurgy (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Medicinal Preparation (AREA)
IL11019094A 1993-07-09 1994-07-01 Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity IL110190A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (2)

Publication Number Publication Date
IL110190A0 IL110190A0 (en) 1994-10-21
IL110190A true IL110190A (en) 2000-07-26

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11019094A IL110190A (en) 1993-07-09 1994-07-01 Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity

Country Status (41)

Country Link
US (1) US5900424A (ja)
EP (2) EP0707580B1 (ja)
JP (2) JP3635432B2 (ja)
KR (1) KR100353783B1 (ja)
CN (1) CN1064680C (ja)
AT (1) ATE212628T1 (ja)
AU (1) AU679766B2 (ja)
BR (1) BR9406940A (ja)
CA (1) CA2166794C (ja)
CZ (1) CZ288933B6 (ja)
DE (2) DE707580T1 (ja)
DK (1) DK0707580T3 (ja)
DZ (1) DZ1792A1 (ja)
EE (1) EE03127B1 (ja)
EG (1) EG21437A (ja)
ES (1) ES2100136T3 (ja)
FI (1) FI114154B (ja)
GR (1) GR970300015T1 (ja)
HR (1) HRP940385B1 (ja)
HU (1) HU226861B1 (ja)
IL (1) IL110190A (ja)
IS (1) IS2075B (ja)
MA (1) MA23257A1 (ja)
MX (1) MX9405217A (ja)
MY (1) MY113274A (ja)
NO (1) NO308702B1 (ja)
NZ (1) NZ268693A (ja)
PL (1) PL175999B1 (ja)
PT (1) PT707580E (ja)
RU (1) RU2139868C1 (ja)
SA (1) SA94150058B1 (ja)
SE (1) SE9302396D0 (ja)
SG (1) SG52464A1 (ja)
SI (1) SI0707580T1 (ja)
SK (1) SK281230B6 (ja)
TN (1) TNSN94079A1 (ja)
TW (1) TW504509B (ja)
UA (1) UA43343C2 (ja)
WO (1) WO1995001977A1 (ja)
YU (1) YU49193B (ja)
ZA (1) ZA944933B (ja)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
ES2100142T3 (es) 1994-07-08 2002-03-01 Astrazeneca Ab Forma de dosificacion en tabletas i constituida por unidades multiples.
FI970058A0 (fi) * 1994-07-08 1997-01-07 Astra Ab Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
KR100619200B1 (ko) * 1998-11-18 2006-09-05 아스트라제네카 아베 개선된 화학적 제조 방법 및 제약 제형
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
WO2001087831A2 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
CN1897924B (zh) 2003-09-26 2011-09-21 阿尔扎公司 能提供高载药量的药物包衣和提供它的方法
RU2257890C2 (ru) * 2003-10-06 2005-08-10 Марио Атилио Лос Способ получения устойчивых фармацевтических композиций в форме таблеток, содержащих омепразол, и фармацевтические композиции, полученные таким способом
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
ES2511792T3 (es) 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
KR20120093140A (ko) * 2009-06-25 2012-08-22 포젠 인크. 아스피린 치료를 필요로 하는 환자의 치료 방법
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
TW504509B (en) 2002-10-01
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
FI960101L (fi) 1996-01-09
HU226861B1 (en) 2009-12-28
NO960068L (no) 1996-01-05
EP1164132A3 (en) 2002-01-02
JP3878826B2 (ja) 2007-02-07
EP0707580B1 (en) 2002-01-30
EG21437A (en) 2001-10-31
JPH08512315A (ja) 1996-12-24
NO308702B1 (no) 2000-10-16
ES2100136T3 (es) 2002-09-01
MA23257A1 (fr) 1995-04-01
AU679766B2 (en) 1997-07-10
CN1064680C (zh) 2001-04-18
UA43343C2 (uk) 2001-12-17
HUT75314A (en) 1997-05-28
MX9405217A (es) 1995-01-31
JP2002105072A (ja) 2002-04-10
DE69429774D1 (de) 2002-03-14
NZ268693A (en) 1997-05-26
DZ1792A1 (fr) 2002-02-17
IL110190A0 (en) 1994-10-21
HU9503873D0 (en) 1996-02-28
PL175999B1 (pl) 1999-03-31
DK0707580T3 (da) 2002-04-15
HRP940385A2 (en) 1997-02-28
EP0707580A1 (en) 1996-04-24
PT707580E (pt) 2002-06-28
ZA944933B (en) 1995-02-20
SA94150058B1 (ar) 2006-06-20
IS2075B (is) 2005-12-15
CZ6996A3 (en) 1996-05-15
HK1008329A1 (en) 1999-05-07
CA2166794C (en) 1997-03-04
YU43694A (sh) 1997-07-31
DE69429774T2 (de) 2002-11-14
MY113274A (en) 2002-01-31
CN1126993A (zh) 1996-07-17
DE707580T1 (de) 1997-09-04
HRP940385B1 (en) 2003-06-30
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
RU2139868C1 (ru) 1999-10-20
CZ288933B6 (cs) 2001-09-12
ES2100136T1 (es) 1997-06-16
YU49193B (sh) 2004-09-03
GR970300015T1 (en) 1997-05-31
WO1995001977A1 (en) 1995-01-19
EP1164132A2 (en) 2001-12-19
FI960101A0 (fi) 1996-01-09
SE9302396D0 (sv) 1993-07-09
SI0707580T1 (en) 2002-06-30
TNSN94079A1 (fr) 1995-04-25
SG52464A1 (en) 1998-09-28
IS4186A (is) 1995-01-10
AU7198194A (en) 1995-02-06
BR9406940A (pt) 1996-09-10
NO960068D0 (no) 1996-01-05
ATE212628T1 (de) 2002-02-15
EE03127B1 (et) 1998-10-15
JP3635432B2 (ja) 2005-04-06
FI114154B (fi) 2004-08-31
PL312440A1 (en) 1996-04-29

Similar Documents

Publication Publication Date Title
IL110190A (en) Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity
HUT45194A (en) Process for production of medical composition
CA2075454A1 (en) Melt cocrystallised sorbitol/xylitol compositions
EP0404283A3 (de) 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
HUT46664A (en) Process for producing new dihydropyridineamide derivatives and pharmaceutical compositions comprising these compounds
CA2035841A1 (en) Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
AU7266291A (en) A novel substituted-amine compound and a process for the preparation thereof
EP0497978A4 (en) Cephalosporin compounds and production thereof
HU9302778D0 (en) Process for preparing acyl-sulfonamido-and sulfonamido-pyridine-2-carboxylic acid esters and pharmaceutical compositions containing them
HUT55033A (en) Process for producing aminooligohydroxy derivatives and pharmaceutical compositions comprising same
HUT69696A (en) Method for producing a novel physical modification of a carbamoylindole derivative and the pharmaceutical compositions comprising it

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired